Document Detail

Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia.
MedLine Citation:
PMID:  18381138     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Evidence suggesting a beneficial effect of cardioprotective medications in patients with lower extremity atherosclerosis derives largely from secondary prevention studies of heterogeneous populations. Patients with critical limb ischemia (CLI) have a large atherosclerotic burden with related high mortality. The effect of such therapies in this population is largely inferred and unproven.
METHODS: The Project of Ex-Vivo vein graft Engineering via Transfection III (PREVENT III) cohort comprised 1404 patients with CLI who underwent lower extremity bypass grafting in a multicenter, randomized prospective trial testing the efficacy of edifoligide for the prevention of graft failure. Propensity scores were used to evaluate the influence of statins, beta-blockers, and antiplatelet agents on outcomes while adjusting for demographics, comorbidities, medications, and surgical variables that may influence drug use. Primary outcomes were major adverse cardiovascular events < or =30 days, vein graft patency, and 1-year survival assessed by Kaplan-Meier method. Potential determinants of 1-year survival were modeled using a multivariate Cox regression.
RESULTS: In this cohort, 636 patients (45%) were taking statins, 835 (59%) were taking beta-blockers, and 1121 (80%) were taking antiplatelet drugs. Perioperative major adverse cardiovascular events (7.8%) and early mortality (2.7%) were not measurably affected by the use of any drug class. Statin use was associated with a significant survival advantage at 1 year of 86% vs 81% (hazard ratio [HR], 0.71; 95% confidence interval [CI], 0.52-0.98; P = .03) by analysis of both unweighted and propensity score-weighted data. Use of beta-blockers and antiplatelet drugs had no appreciable impact on survival. None of the drug classes were associated with graft patency measures at 1 year. Significant predictors of 1-year mortality by Cox regression modeling were statin use (HR, 0.67; 95% CI, 0.51-0.90; P = .001), age >75 (HR, 2.1; 95% CI, 1.60-2.82; P = .001), coronary artery disease (HR, 1.5; 95% CI, 1.15-2.01; P = .001), chronic kidney disease stages 4 (HR, 2.0; 95% CI, 1.17-3.55; P = .001) and 5 (HR, 3.4; 95% CI, 2.39-4.73; P < .001), and tissue loss (HR, 1.9; 95% CI, 1.23-2.80; P = .003).
CONCLUSIONS: Statin use is associated with improved survival in CLI patients 1 year after surgical revascularization. Further studies are indicated to determine optimal dosing in this population and to definitively address the question of relationship to graft patency. These data add to the growing literature supporting statin use in patients with advanced peripheral arterial disease.
Andres Schanzer; Nathanael Hevelone; Christopher D Owens; Joshua A Beckman; Michael Belkin; Michael S Conte
Related Documents :
22285258 - Functional outcomes for 2 years comparing hip resurfacing and total hip arthroplasty.
22572608 - Acute and long-term outcomes of catheter ablation using remote magnetic navigation in p...
15765908 - Uncomplicated carotid endarterectomy: factors contributing to blood pressure instabilit...
22681318 - Stereotactic endoscopic placement of third ventricle catheter for long-term infusion of...
24421318 - Patient acceptable symptom states after totalhip or knee replacement at mid-term follow...
22626878 - Effect of stroke volume variability-guided intraoperative fluid restriction on gastroin...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of vascular surgery     Volume:  47     ISSN:  0741-5214     ISO Abbreviation:  J. Vasc. Surg.     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-04-02     Completed Date:  2008-05-13     Revised Date:  2012-10-03    
Medline Journal Info:
Nlm Unique ID:  8407742     Medline TA:  J Vasc Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  774-781     Citation Subset:  IM    
Division of Vascular and Endovascular Surgery, University of Massachusetts, Worcester, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / therapeutic use
Arteriosclerosis / surgery*
Cardiotonic Agents / therapeutic use*
Cardiovascular Diseases / etiology
Graft Survival / drug effects
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Ischemia / mortality*,  surgery*
Leg / blood supply*
Oligonucleotides / therapeutic use
Platelet Aggregation Inhibitors / therapeutic use
Prospective Studies
Transplantation, Autologous
Vascular Patency / drug effects
Veins / transplantation
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Cardiotonic Agents; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Oligonucleotides; 0/Platelet Aggregation Inhibitors; 0/edifoligide
Comment In:
J Vasc Surg. 2009 Jun;49(6):1635; author reply 1636   [PMID:  19201143 ]
J Vasc Surg. 2008 Dec;48(6):1639-40; author reply 1640   [PMID:  19118751 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lessons learned from midterm follow-up of endovascular repair for traumatic rupture of the aortic is...
Next Document:  A prospective comparison of bilateral photoplethysmography versus the ankle-brachial pressure index ...